Senti Biosciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(12,111) | $(18,722) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 984 | 467 |
| Amortization of operating lease right-of-use assets | 477 | 462 |
| Accretion of discount on short-term investments | — | (572) |
| Change in fair value of contingent earnout liability | — | (59) |
| Change in fair value of GeneFab Note Receivable - related party | (29) | — |
| Change in fair value of GeneFab Economic Share - related party | (55) | — |
| Change in fair value of GeneFab Option - related party | (2,314) | — |
| Stock-based compensation expense | 1,258 | 3,763 |
| Other non-cash charges | 38 | (30) |
| Changes in assets and liabilities: | ||
| Accounts receivable | — | (135) |
| GeneFab receivable - related party | 21 | — |
| GeneFab prepaid expenses - related party | 3,487 | — |
| Prepaid expenses and other assets | 192 | (402) |
| Accounts payable | 389 | 280 |
| Accrued expenses and other current liabilities | (2,946) | (1,846) |
| GeneFab sublease deferred income - related party | (127) | — |
| Deferred revenue | — | (392) |
| Operating lease liabilities | (946) | 882 |
| Net cash from operating activities | (11,682) | (16,304) |
| Cash flows from investing activities | ||
| Purchases of short-term investments | — | (17,990) |
| Maturities of short-term investments | — | 15,000 |
| Purchases of property and equipment | (15) | (6,507) |
| Net cash from investing activities | (15) | (9,497) |
| Cash flows from financing activities | ||
| Principal finance lease payments | — | (35) |
| Net cash from financing activities | — | (35) |
| Net decrease in cash and cash equivalents | (11,697) | (25,836) |
| Cash, cash equivalents, and restricted cash, beginning of period | 39,448 | 60,987 |
| Cash, cash equivalents, and restricted cash, end of period | $27,751 | $35,151 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $23,723 | $31,600 |
| Restricted cash | 4,028 | 3,551 |
| Total | $27,751 | $35,151 |
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental disclosures of noncash investing and financing and items | ||
| Purchases of property and equipment in accounts payable and accrued expenses | $— | $4,758 |
| Refer to Note 3. GeneFab Transaction for details of non-cash items | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.